graphic
abstract
highlight
sever
patient
display
immun
dysregul
macrophag
activ
syndrom
sever
respiratori
failur
associ
major
decreas
hladr
monocyt
cell
nk
cell
cytopenia
characterist
sever
blocker
tocilizumab
partial
rescu
immun
dysregul
proper
manag
mandat
better
understand
diseas
pathogenesi
giamarellosbourbouli
et
al
describ
two
main
featur
preced
sever
respiratori
failur
associ
first
macrophag
activ
syndrom
second
defect
antigenpresent
driven
blocker
partial
rescu
immun
dysregul
vitro
patient
decemb
author
wuhan
china
report
cluster
pneumonia
case
caus
unknown
etiolog
agent
pathogen
soon
identifi
sequenc
novel
coronaviru
relat
agent
sever
acut
respiratori
syndrom
sar
subsequ
term
sar
infect
spread
subsequ
month
contin
declar
pandem
world
health
organ
april
document
case
report
worldwid
patient
die
http
wwwwhointemergenciesdiseas
novel
coronaviru
tropism
lung
caus
communityacquir
pneumonia
cap
patient
pneumonia
suddenli
deterior
sever
respiratori
failur
srf
requir
intub
mechan
ventil
mv
risk
death
patient
high
reach
even
arabi
et
al
proper
manag
mandat
better
understand
diseas
pathogenesi
major
physician
use
sepsi
prototyp
critic
ill
understand
sever
coronaviru
diseas
pathogenesi
mostli
sever
associ
hypercytokinemia
guan
et
al
huang
et
al
lethal
sepsi
commonli
aris
bacteri
cap
often
lead
srf
need
mv
peculiar
clinic
cours
cap
caus
includ
sudden
deterior
clinic
condit
day
first
symptom
gener
hypothesi
ill
driven
uniqu
pattern
immun
dysfunct
like
differ
sepsi
featur
lymphopenia
hepat
dysfunct
increas
ddimer
qin
et
al
patient
sever
diseas
support
hypothesi
immun
respons
critic
ill
patient
sepsi
classifi
three
pattern
macrophageactiv
syndrom
ma
kyriazopoul
et
al
sepsisinduc
immunoparalysi
character
low
express
human
leukocyt
antigen
relat
hladr
monocyt
lukaszewicz
et
al
intermedi
function
state
immun
system
lack
obviou
dysregul
investig
whether
classif
might
appli
patient
srf
caus
result
reveal
approxim
one
fourth
patient
srf
ma
patient
suffer
immun
dysregul
domin
low
express
hladr
monocyt
trigger
monocyt
hyperactiv
excess
releas
profound
lymphopenia
pattern
distinct
immunoparalysi
state
report
either
bacteri
sepsi
srf
caus
influenza
patient
sever
respiratori
failur
caus
immun
dysregul
ma
assess
differ
immun
activ
dysregul
known
sever
infect
three
patient
cohort
patient
sepsi
caus
bacteri
cap
histor
patient
influenza
patient
cap
caus
patient
bacteri
cap
screen
particip
largescal
random
clinic
trial
acronym
provid
clinicaltrialsgov
patient
influenza
describ
previou
public
group
giamarellosbourbouli
et
al
raftogianni
et
al
clinic
characterist
patient
bacteri
cap
cap
caus
describ
tabl
cohort
bacteri
sepsi
split
patient
develop
srf
requir
mv
three
main
featur
need
outlin
patient
srf
less
sever
sever
bacteri
cap
basi
tradit
sever
score
sequenti
organ
failur
assess
sofa
acut
physiolog
chronic
health
evalu
apach
ii
lead
conclus
patient
undergo
acut
immun
dysregul
deterior
srf
overal
state
sever
advanc
although
burden
comorbid
patient
express
charlson
comorbid
index
higher
among
patient
srf
among
patient
without
srf
remain
remark
lower
tradit
bacteri
cap
sepsi
also
notabl
admiss
valu
glasgow
coma
scale
score
patient
bacteri
cap
patient
p
find
fulli
compat
clinic
descript
sever
patient
admit
rel
good
clinic
state
suddenli
deterior
coronari
heart
diseas
comparison
respect
group
without
respiratori
failur
student
test
pnonsignific
p
p
p
abbrevi
follow
alt
alanin
aminotransferas
aptt
activ
partial
thromboplastin
time
ast
aspart
aminotransferas
apach
acut
physiolog
chronic
health
evalu
cci
charlson
comorbid
index
inr
intern
normal
ratio
psi
pneumonia
sever
index
sd
standard
deviat
sofa
sequenti
organ
failur
assess
immun
classif
patient
perform
use
tool
suggest
bacteri
sepsi
ie
ferritin
ngml
ma
kyriazopoul
et
al
hladr
molecul
monocyt
lower
absenc
elev
ferritin
immun
dysregul
phenotyp
lukaszewicz
et
al
found
contrari
patient
bacteri
cap
srf
patient
srf
either
immun
dysregul
ma
tabl
major
decreas
hladr
monocyt
associ
srf
immunoparalysi
sepsi
character
signific
decreas
number
hladr
molecul
monocyt
also
happen
immun
dysregul
caus
figur
although
patient
bacterialcapassoci
ma
also
decreas
hladr
molecul
monocyt
circul
ferritin
significantli
higher
normal
featur
found
patient
ma
figur
absenc
trait
ma
among
case
immun
dysregul
proven
low
score
hemophagocytosi
hs
hscore
propos
classif
tool
secondari
ma
valu
highli
diagnost
fardet
et
al
seven
patient
hs
cutoff
properli
classifi
use
ferritin
figur
among
patient
bacteri
cap
intermedi
immun
state
number
molecul
hladr
monocyt
lower
healthi
patient
howev
patient
pneumonia
caus
intermedi
immun
state
maintain
number
molecul
hladr
monocyt
much
closer
healthi
condit
number
suddenli
drop
srf
superven
figur
moreov
absolut
count
neutrophil
monocyt
higher
among
patient
immun
dysregul
patient
ma
figur
absolut
count
lymphocyt
lymphocyt
cell
lymphocyt
lower
among
patient
compar
healthi
subject
adjust
age
gender
compar
patient
cap
caus
patient
lower
lymphocyt
higher
cell
lymphocyt
figur
patient
immun
dysregul
caus
lower
count
lymphocyt
lymphocyt
cell
intermedi
immun
state
comparison
limit
patient
srf
infect
one
two
virus
found
infect
accompani
lower
lymphocyt
higher
cell
lymphocyt
figur
function
assess
product
capac
downregul
among
patient
immun
dysregul
figur
next
question
chang
lymphocyt
translat
serum
immunoglobulin
ig
concentr
igg
subclass
plasma
patient
low
bacteri
cap
figur
howev
igm
iga
higher
bacteri
cap
figur
overal
patient
ma
lower
igm
iga
intermedi
immun
state
patient
immun
dysregul
lower
igm
intermedi
immun
state
blocker
tocilizumab
partial
rescu
immun
dysregul
driven
sepsisinduc
immunoparalysi
character
profound
defici
monocyt
cytokin
product
upon
ex
vivo
stimul
giamarellosbourbouli
et
al
inde
product
tumor
necrosi
factora
tnfa
lpsstimul
peripher
blood
mononuclear
cell
pbmc
patient
bacteri
cap
classifi
immunoparalysi
significantli
lower
patient
intermedi
state
figur
case
patient
pneumonia
caus
pbmc
show
sustain
tnfa
product
stimul
lp
figur
function
pbmc
patient
srf
caus
also
impair
lower
tnfa
product
pattern
differ
patient
figur
surprisingli
stimul
lower
among
patient
immun
dysregul
among
patient
intermedi
immun
state
figur
howev
follow
stimul
pattern
tnfa
figur
gener
hypothesi
case
srfaggrav
pneumonia
caus
uniqu
combin
defect
antigen
present
lymphopenia
lead
defect
function
lymphoid
cell
wherea
monocyt
remain
potent
product
tnfa
next
step
measur
circul
concentr
tnfa
interferong
ifng
creactiv
protein
crp
patient
infect
ifng
limit
detect
patient
data
shown
indic
respons
contribut
overinflamm
differ
circul
tnfa
concentr
found
patient
three
state
immun
classif
figur
contrast
crp
concentr
significantli
higher
among
patient
immun
dysregul
among
patient
intermedi
state
immun
activ
figur
given
limit
detect
patient
immun
dysregul
divid
two
group
follow
seven
patient
limit
detect
patient
detect
sever
similar
given
sofa
score
pneumonia
sever
index
similar
p
valu
comparison
respect
data
shown
known
inhibit
hladr
express
ohno
et
al
lead
hypothesi
overproduct
mediat
low
hladr
express
monocyt
patient
agreement
neg
correl
found
serum
amount
absolut
number
hladr
molecul
monocyt
patient
also
absolut
lymphocyt
count
absolut
number
mhladr
monocyt
patient
figur
furthermor
pbmc
patient
immun
dysregul
cultur
overnight
presenc
plasma
patient
alreadi
shown
rich
express
hladr
monocyt
strongli
inhibit
plasma
patient
immun
dysregul
plasma
patient
intermedi
immun
state
activ
figur
addit
specif
blocker
pathway
tocilizumab
partial
restor
express
hladr
monocyt
patient
immun
dysregul
figur
treatment
tocilizumab
six
patient
accompani
increas
absolut
lymphocyt
blood
count
within
first
h
figur
produc
partli
monocyt
partli
cell
figur
fj
absolut
count
lymphocyt
f
lymphocyt
g
lymphocyt
h
cell
lymphocyt
j
among
patient
sever
respiratori
failur
develop
field
cap
caus
influenza
viru
patient
pneumonia
caus
develop
srf
display
hyperinflammatori
respons
featur
either
immun
dysregul
ma
character
proinflammatori
cytokin
immun
dysregul
describ
driven
ma
driven
two
key
featur
immun
dysregul
overproduct
proinflammatori
cytokin
monocyt
dysregul
lymphocyt
character
lymphopenia
subsequ
b
cell
lymphopenia
parallel
absolut
natur
killer
nk
cell
count
deplet
probabl
result
rapidli
propag
viru
previous
shown
addit
growth
medium
healthi
dendrit
cell
attenu
hladr
membran
express
decreas
product
ifng
cell
ohno
et
al
three
find
studi
compat
propos
one
driver
decreas
hladr
monocyt
concentr
blood
invers
associ
hladr
express
figur
addit
tocilizumab
plasmaenrich
medium
cell
partial
restor
express
hladr
cell
membran
figur
absolut
lymphocyt
count
six
patient
increas
tocilizumab
treatment
figur
find
indirectli
support
increas
circul
hladr
cell
convalesc
one
case
moder
sever
thevarajan
et
al
conclus
identifi
uniqu
signatur
immun
dysregul
patient
character
one
hand
normal
high
cytokin
product
capac
bar
graphic
repres
mean
valu
standard
error
statist
signific
comparison
indic
arrow
p
p
p
comparison
done
mannwhitney
u
test
follow
correct
multipl
comparison
k
product
pbmc
stimul
heatkil
candida
albican
bar
graphic
repres
mean
valu
standard
error
statist
comparison
indic
arrow
ns
nonsignific
p
p
p
p
comparison
done
mannwhitney
u
test
follow
correct
multipl
comparison
legend
continu
next
page
increas
circul
cytokin
especi
hand
defect
lymphoid
function
associ
decreas
hladr
express
find
support
rational
launch
clinic
trial
efficaci
anakinra
sarilumab
siltuximab
tocilizumab
clinicaltrialsgov
eudract
number
elabor
antiinflammatori
respons
patient
bar
graphic
repres
mean
valu
standard
error
statist
comparison
indic
arrow
ns
nonsignific
p
p
p
p
comparison
done
mannwhitney
u
test
follow
correct
multipl
comparison
six
patient
immun
dysregul
treat
singl
intraven
infus
mgkg
tocilizumab
roacremra
roch
base
nation
health
care
offlabel
provis
absolut
lymphocyt
blood
count
compar
tocilizumab
infus
qualit
data
present
percentag
confid
interv
ci
compar
fisher
exact
test
qualit
data
present
mean
standard
deviat
compar
student
ttest
present
mean
standard
error
compar
mannwhitney
u
test
small
group
pair
comparison
done
wilcoxon
ranksign
test
nonparametr
correl
done
accord
spearman
valu
p
consid
signific
